BioCryst Pharmaceuticals | BCRX - Nettoeinkommen





Nettoeinkommen Veränderung Datum
Alnylam Pharmaceuticals USD 205.99M 19.57M 2026-03
BioCryst Pharmaceuticals USD 245.84M 232.95M 2025-12
Chugai Pharma JPY 115.42B 12.99B 2026-03
Daiichi Sankyo JPY 86.63B 41.32B 2025-12
DBV Technologies USD -33.16M 8.71M 2025-09
Enanta Pharmaceuticals USD -22.29M 93.76M 2024-12
Gilead Sciences USD 2.02B 162M 2026-03
GlaxoSmithKline GBP 1.74B 1.1B 2026-03
Glaxosmithkline GBP 846.06M 1.87B 2025-12
Incyte USD 303.33M 4.05M 2026-03
Ionis Pharmaceuticals USD -93M 136M 2026-03
Karyopharm Therapeutics USD -102.2M 71.42M 2025-12
Neurocrine Biosciences USD 197.9M 44.2M 2026-03
Novavax USD 17.53M 219.91M 2025-12
PTC Therapeutics USD -2.81M 132.16M 2026-03
Regeneron Pharmaceuticals USD 727.2M 117.4M 2026-03
Roche Holding CHF 5.47B 1.76B 2025-12
Sarepta Therapeutics USD 330.96M 743.18M 2026-03
Ultragenyx Pharmaceutical USD -185M 56M 2026-03
Vertex Pharmaceuticals USD 1.03B 159.7M 2026-03